Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 128Gynecologic 5Other 3Thoracic 2Genitourinary 2Tumor-Agnostic 1Other neoplasm 1Gastrointestinal 1Endocrine 1

Conditions

Hormone Receptor Positive Malignant Neoplasm of Breast 1

Interventions

Surveys and Questionnaires 9Cyclophosphamide 9Whole-Body Irradiation 7Biopsy 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Educational Status 6Early Intervention, Educational 6Busulfan 6Methotrexate 5Methods 5Immunohistochemistry 5Epoetin Alfa 5Tacrolimus 4Mycophenolic Acid 4Interviews as Topic 4Gene Expression Profiling 4Decitabine 4Cyclosporine 4Celecoxib 4Antilymphocyte Serum 4fludarabine 3Sirolimus 3Radiotherapy 3Paclitaxel 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Imiquimod 3Fentanyl 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × exemestane × Other neoplasm × Clear all
NCT02025712 2014-01-01

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Organisation for Oncology and Translational Research

Phase 2 Unknown
35 enrolled
BreastOther neoplasm

Hormone Receptor Positive Malignant Neoplasm of Breast

Data powered by HemOnc (CC BY 4.0) Colophon âš¡